Latest news with #AcurxPharmaceuticals
Miami Herald
a day ago
- Business
- Miami Herald
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days
PetVivo and Acurx Pharmaceuticals Exceed 200,000 Views as investor Demand for Long-Form Corporate Storytelling Surges NEW YORK CITY, NEW YORK / ACCESS Newswire / June 9, 2025 / New to The Street, the nation's leading financial media brand for long-form investor communications, proudly announces record-breaking viewership across its newest documentary-style programs. Its latest feature on IMG Academy surpassed 126,000 views in only 12 days on YouTube, marking a new milestone for the brand's flagship long-form format. Meanwhile, features on PetVivo Holdings, Inc. (NASDAQ:PETV) and Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) have crossed 200,000 views, reinforcing New to The Street's position as a go-to media platform for delivering cinematic, investor-focused storytelling at scale. Watch the full specials here: IMG Academy: PetVivo: Acurx Pharmaceuticals: Since 2009, New to The Street has produced thousands of 7-10-minute segments featuring public company CEOs and C-suite leaders, broadcast as sponsored programming on Bloomberg Television and FOX Business. The addition of 27-28-minute documentary specials represents a strategic evolution in media format-now delivering immersive brand narratives that are licensed, broadcast, and featured across a YouTube network with more than 2.5 million subscribers. Following national TV exposure, these pieces are supported by earned media syndication, social media campaigns, and Times Square billboard placements-providing a 360° distribution model for maximum investor engagement. For media, sponsorship, or booking inquiries, contact:Monica BrennanMonica@ About New to The Street:New to The Street is a nationally syndicated financial media platform delivering long-form television interviews, corporate documentaries, and multi-channel distribution across Bloomberg TV, FOX Business, as sponsored programming and one of the largest business YouTube channels in the industry. With over 245 million weekly household reach and 2.54M+ subscribers, the brand is redefining how business stories are told-and seen. SOURCE: New To The Street
Associated Press
2 days ago
- Business
- Associated Press
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days
PetVivo and Acurx Pharmaceuticals Exceed 200,000 Views as investor Demand for Long-Form Corporate Storytelling Surges NEW YORK CITY, NEW YORK / ACCESS Newswire / June 9, 2025 / New to The Street, the nation's leading financial media brand for long-form investor communications, proudly announces record-breaking viewership across its newest documentary-style programs. Its latest feature on IMG Academy surpassed 126,000 views in only 12 days on YouTube, marking a new milestone for the brand's flagship long-form format. Meanwhile, features on PetVivo Holdings, Inc. (NASDAQ:PETV) and Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) have crossed 200,000 views, reinforcing New to The Street's position as a go-to media platform for delivering cinematic, investor-focused storytelling at scale. Watch the full specials here: 'These are not typical interviews-they're broadcast-quality mini-documentaries that resonate across investor and consumer audiences alike,' said Vince Caruso, Co-Founder and CEO of New to The Street. 'We're combining Wall Street-level insight with storytelling that connects emotionally and visually. Companies are seeing it translate directly into visibility and traction.' Since 2009, New to The Street has produced thousands of 7-10-minute segments featuring public company CEOs and C-suite leaders, broadcast as sponsored programming on Bloomberg Television and FOX Business. The addition of 27-28-minute documentary specials represents a strategic evolution in media format-now delivering immersive brand narratives that are licensed, broadcast, and featured across a YouTube network with more than 2.5 million subscribers. Following national TV exposure, these pieces are supported by earned media syndication, social media campaigns, and Times Square billboard placements-providing a 360° distribution model for maximum investor engagement. 'The data is crystal clear-audiences are spending more time with high-quality, long-form content,' added Caruso. 'This format allows companies to fully control their narrative, showcase innovation, and build trust-all while generating viewership numbers that rival traditional media.' For media, sponsorship, or booking inquiries, contact: Monica Brennan [email protected] About New to The Street: New to The Street is a nationally syndicated financial media platform delivering long-form television interviews, corporate documentaries, and multi-channel distribution across Bloomberg TV, FOX Business, as sponsored programming and one of the largest business YouTube channels in the industry. With over 245 million weekly household reach and 2.54M+ subscribers, the brand is redefining how business stories are told-and seen. SOURCE: New To The Street press release
Business Insider
17-05-2025
- Business
- Business Insider
H.C. Wainwright Resumes Coverage with a Buy Rating on Acurx Pharmaceuticals (ACXP)
In a report released on May 15, Matthew Keller from H.C. Wainwright resumed coverage with a Buy rating on Acurx Pharmaceuticals (ACXP – Research Report) and a price target of $8.00. The company's shares closed yesterday at $0.39. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Keller is an analyst with an average return of -24.9% and a 0.00% success rate. Keller covers the Healthcare sector, focusing on stocks such as FibroGen, Iterum Therapeutics, and GRI Bio. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Acurx Pharmaceuticals with a $6.17 average price target, which is a 1,494.32% upside from current levels. In a report released on May 14, Maxim Group also maintained a Buy rating on the stock with a $1.50 price target. Based on Acurx Pharmaceuticals' latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $2.15 billion. In comparison, last year the company had a GAAP net loss of $4.38 million
Yahoo
04-04-2025
- Business
- Yahoo
Acurx Pharmaceuticals, Inc. (ACXP): Insider Were Buying In Q1 2025
We recently published a list of . In this article, we are going to take a look at where Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) stands against other micro-cap stocks insiders were buying in Q1 2025. The White House announced Tuesday that Trump's tariffs would take effect immediately after being unveiled on Wednesday. In anticipation of these 'reciprocal tariffs,' which will apply to all countries, the stock market reacted. By Tuesday morning, the broader market index and Nasdaq Composite dropped by about 0.2%, while blue-chip companies lost 0.06%. Amid ongoing market uncertainty, insider trading often comes under the spotlight. Executive stock purchases can signal optimism, but sales may reflect personal financial decisions or a need to diversify investments. To maintain transparency, executives typically follow pre-arranged strategies, like 10b5-1 plans. While insider trading can offer valuable information, it's important to evaluate it in the broader context of the company's financial stability and current market trends. Today, we're focusing on stocks with micro market capitalizations that have seen significant insider buying in the first quarter of the year. Using Insider Monkey's insider trading screener, we identified companies with market caps under $250 million where at least three insiders purchased shares in the past three months. From this list, we ranked the top 10 stocks with the highest number of insiders making purchases. Stocks that have been recently covered were excluded from our analysis. Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). With each stock, we note the number of insiders who acquired shares in the first quarter and market capitalizations. A microbiologist in a lab coat, examining a sample of Gram-positive bacteria. Number of insiders buying: 6 Market Capitalization: $8.36 million Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing antibiotics to treat bacterial infections, with its lead candidate, ibezapolstat, currently in Phase 2b trials for Clostridium difficile infections. The Staten Island, New York-based company also develops ACX-375C, a potential treatment for gram-positive bacteria, including resistant strains like MRSA and VRE. It ranks first among 10 micro-cap stocks insiders were buying in the first quarter of 2025. During the first quarter, six insiders, including the president and CEO acquired around $170,000 worth of Acurx shares at an average price of $1.02 per share. Currently, the stock trades at $0.38 per share, having lost 53.17% year-to-date and 82.52% over the past 12 months. For the full year 2024, Acurx reported a net loss of $14.1 million or $0.87 per share, compared to a net loss of $14.6 million or $1.15 per share in 2023. General and administrative expenses reached $8.7 million, compared to $8.5 million in the prior year. The increase was primarily due to a $700,000 increase in professional fees, a $300,000 increase in legal fees, offset by a $600,000 decrease in share-based compensation costs and a $200,000 decrease in insurance costs. Research and development expenses were $5.4 million compared to $6.0 million in 2023. The company ended the year with cash totaling $3.7 million, compared to $7.5 million as of December 31, 2023. One analyst has given Acurx stock a 'Strong Buy' rating, with a 12-month price target of $12.00, reports StockAnalysis. Overall, ACXP ranks 1st on our list of micro-cap stocks insiders were buying in Q1 2025. While we acknowledge the potential of ACXP our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ACXP but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Associated Press
14-03-2025
- Business
- Associated Press
New to The Street & Sight & Sound's Visionaries Series Premieres Tomorrow on Bloomberg at 6:30 PM EST, Featuring Acurx Pharmaceuticals NASDAQ:ACXP
NEW YORK CITY, NEW YORK / ACCESS Newswire / March 14, 2025 / The highly anticipated Visionaries Series from New to The Street and Sight & Sound premieres tomorrow on Bloomberg at 6:30 PM EST as sponsored programming, featuring Acurx Pharmaceuticals. This compelling episode follows the incredible journey of co-founders David P. Luci, Robert J. DeLuccia, and Robert G. Shawah - from their college days to building and exiting successful pharmaceutical companies, and ultimately coming together to launch Acurx Pharmaceuticals. The series explores the vision, perseverance, and expertise that led them to develop groundbreaking antibiotics, addressing urgent global health challenges with innovative treatments. About New to The Street New to The Street is a premier televised business program that has been showcasing innovative companies and industry leaders for over 15 years. Airing as sponsored programming on Fox Business, Bloomberg, and major networks, the show provides national TV exposure, earned media coverage, and strategic outdoor advertising. With over 2.4 million YouTube subscribers, New to The Street delivers compelling content that reaches investors, consumers, and business leaders worldwide. About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. The company's Gram-positive selective spectrum (GPSS®) technology targets DNA polymerase IIIC (pol IIIC), an essential bacterial enzyme, effectively stopping bacterial replication and leading to cell death. Acurx's lead product candidate, ibezapolstat, is Phase 3 ready for the treatment of Clostridioides difficile (C. difficile) infection, with international clinical trials set to begin this year. The company is also advancing a novel oral antibiotic for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and developing a parallel program for inhaled anthrax treatment. Meet the Founding Team: From College to Biotech Success David P. Luci - Co-Founder, President & CEO David P. Luci began his career in finance and corporate law, before moving into biotech leadership. He co-founded Acurx Pharmaceuticals after serving as President & CEO of Dipexium Pharmaceuticals (Nasdaq:DPRX), where he successfully led its $69 million merger with PLx Pharma Inc. (Nasdaq:PLXP). With a background in healthcare finance at Ernst & Young LLP and corporate law at Paul Hastings LLP, Mr. Luci has been a driving force in biotech innovation and M&A transactions. Robert J. DeLuccia - Co-Founder, Executive Chairman Robert J. DeLuccia's executive leadership and marketing expertise have been instrumental in the growth of multiple pharmaceutical companies. Before co-founding Acurx, he was Executive Chairman of Dipexium Pharmaceuticals, leading it through a successful exit. He previously served as CEO of Immunomedics, Inc., President of Sterling Winthrop, and held senior leadership roles at Pfizer. His strategic vision and business development acumen have helped shape Acurx's long-term success. Robert G. Shawah, CPA - Co-Founder & Chief Financial Officer Robert G. Shawah is the financial backbone of Acurx Pharmaceuticals. With over 30 years of experience in finance, accounting, and corporate governance, he previously served as Chief Accounting Officer at Dipexium Pharmaceuticals, helping steer the company through its acquisition. His extensive background in financial management and operations includes leadership roles at Arthur Andersen PC and WR Grace & Co. A Story of Innovation, Grit, and Success The Visionaries Series offers a rare glimpse into the founding story of Acurx Pharmaceuticals, from college friendships and early career moves to their breakthroughs in biotech and successful pharma exits. The episode highlights how their combined expertise in finance, corporate strategy, and drug development led to the creation of a company poised to revolutionize antibiotic treatments.
